Meso Scale Discovery V-plex SARS-CoV-2 Panels

Click2Contact

Meso Scale Discovery’s electrochemiluminescence technology eliminates many difficulties associated with commonly used sandwich assay methods, with its high sensitivity and fast, simple workflows allowing for the detection of biomolecules of interest. The use of an electrochemiluminescent label, SULFO-TAG, conjugated to a detection molecule allows for custom-designed and curated panels for a wide variety of biomedical and pharmacologic research applications.

The combination of electrochemiluminescence and arrays brings speed and high density of information to biological assays. The technology is designed to enable precise quantitation of multiple analytes in a single sample requiring less time and effort than other assay platforms. Multi-SPOT plates measuring up to 10 different analytes per well is said to increase throughput and assay multiplexing in 96- and 384-well formats.

The immunoassay technology provides good analytical performance and customer value. The V-plex SARS-CoV-2 Panel 2 was selected by US-government funded initiative Operation Warp Speed as the basis of standard binding assays for immunogenicity assessments in all US-funded Phase III clinical trials of vaccines.

Currently the range of V-plex SARS-CoV-2 Panels includes over 20 different multiplex serology assays and ACE2 neutralisation assays for antibodies to spike, RBD and nucleocapsid antigens from variants of SARS-CoV-2. Panels for over 35 SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, Lambda, Mu and Omicron variants are available and all human V-plex serology panels for the range are provided as complete kits with reference standards and controls.